JP2023527613A5 - - Google Patents
Info
- Publication number
- JP2023527613A5 JP2023527613A5 JP2022551537A JP2022551537A JP2023527613A5 JP 2023527613 A5 JP2023527613 A5 JP 2023527613A5 JP 2022551537 A JP2022551537 A JP 2022551537A JP 2022551537 A JP2022551537 A JP 2022551537A JP 2023527613 A5 JP2023527613 A5 JP 2023527613A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- sequence
- chain containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062981856P | 2020-02-26 | 2020-02-26 | |
| US62/981,856 | 2020-02-26 | ||
| PCT/US2021/019775 WO2021173902A1 (en) | 2020-02-26 | 2021-02-26 | Hla class ii-restricted t cell receptors against ras with g12v mutation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023527613A JP2023527613A (ja) | 2023-06-30 |
| JP2023527613A5 true JP2023527613A5 (enExample) | 2024-03-05 |
| JP7742354B2 JP7742354B2 (ja) | 2025-09-19 |
Family
ID=74885105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551537A Active JP7742354B2 (ja) | 2020-02-26 | 2021-02-26 | Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230159614A1 (enExample) |
| EP (1) | EP4110804A1 (enExample) |
| JP (1) | JP7742354B2 (enExample) |
| KR (1) | KR20220143939A (enExample) |
| CN (1) | CN115244075A (enExample) |
| AU (1) | AU2021225872A1 (enExample) |
| BR (1) | BR112022016661A2 (enExample) |
| CA (1) | CA3169086A1 (enExample) |
| GB (1) | GB2610069B (enExample) |
| MX (1) | MX2022010157A (enExample) |
| TW (1) | TWI900533B (enExample) |
| WO (1) | WO2021173902A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240000834A1 (en) * | 2020-11-24 | 2024-01-04 | Shanghai GenBase Biotechnology Co., Ltd. | Ras mutant epitope peptide and t cell receptor recognizing ras mutant |
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| US20250145950A1 (en) | 2022-02-01 | 2025-05-08 | Alaunos Therapeutics, Inc. | Methods for Activation and Expansion of T Cells |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| KR20250037592A (ko) | 2017-09-20 | 2025-03-17 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 돌연변이된 ras에 대한 hla 클래스 ii-제한된 t 세포 수용체 |
| CR20200287A (es) * | 2017-12-04 | 2020-11-11 | Us Health | Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado |
| WO2019129892A1 (en) * | 2017-12-29 | 2019-07-04 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | T cell receptors for tumor specific proteasome splice variants and uses thereof |
| GB201804724D0 (en) * | 2018-03-23 | 2018-05-09 | Univ Oslo Hf | Method of diagnosing cceliac disease |
| WO2019231326A1 (en) * | 2018-05-31 | 2019-12-05 | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n.LUMC) | Teipp neoantigens and uses thereof |
| WO2022183167A1 (en) * | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
-
2021
- 2021-02-26 EP EP21712694.5A patent/EP4110804A1/en active Pending
- 2021-02-26 US US17/802,464 patent/US20230159614A1/en active Pending
- 2021-02-26 CN CN202180016761.4A patent/CN115244075A/zh active Pending
- 2021-02-26 AU AU2021225872A patent/AU2021225872A1/en active Pending
- 2021-02-26 BR BR112022016661A patent/BR112022016661A2/pt unknown
- 2021-02-26 JP JP2022551537A patent/JP7742354B2/ja active Active
- 2021-02-26 GB GB2212195.8A patent/GB2610069B/en active Active
- 2021-02-26 MX MX2022010157A patent/MX2022010157A/es unknown
- 2021-02-26 KR KR1020227033222A patent/KR20220143939A/ko active Pending
- 2021-02-26 WO PCT/US2021/019775 patent/WO2021173902A1/en not_active Ceased
- 2021-02-26 TW TW110106886A patent/TWI900533B/zh active
- 2021-02-26 CA CA3169086A patent/CA3169086A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023527613A5 (enExample) | ||
| JP7637415B2 (ja) | インターロイキン－２バリアントおよびその使用方法 | |
| JP2021505136A5 (enExample) | ||
| JP2021191265A5 (enExample) | ||
| GB2610311A (en) | HLA class I-restricted T cell receptors against RAS with G12V mutation | |
| Cruikshank et al. | Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. | |
| Zinkernagel et al. | Virus-induced autoantibody response to a transgenic viral antigen | |
| JP2020534828A5 (enExample) | ||
| GB2610069A (en) | HLA class II-restricted T cell receptors against RAS with G12V mutation | |
| US20150368316A1 (en) | A selective high-affinity immune stimulatory reagent and uses thereof | |
| WO2020089433A2 (en) | Tcr and peptides | |
| WO2021102624A1 (en) | Covalent protein drugs developed via proximity-enabled reactive therapeutics (perx) | |
| WO2019112347A2 (ko) | 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도 | |
| CN107207622B (zh) | Hla-b27同二聚体用于癌症治疗的用途 | |
| JP2023534241A5 (enExample) | ||
| KR20210129125A (ko) | Baff-r/cd19 표적화된 키메라 항원 수용체-변형된 t 세포 및 그의 용도 | |
| JP2023544592A5 (enExample) | ||
| EA201001190A1 (ru) | Выделенное антитело, специфически связанное с полипептидом, состоящее из последовательности аминокислотных остатков | |
| JP2022523024A5 (enExample) | ||
| GB2615010A (en) | HLA class II-restricted DQ T cell receptors against RAS with G13D mutation | |
| CA2660064A1 (en) | Promiscuous pap cd4 t cell epitopes | |
| WO2014109289A9 (ja) | ＨＬＡ－ＤＲ１拘束性Ｔａｘ特異的ＣＤ４＋Ｔ細胞エピトープ | |
| JP7796754B2 (ja) | インターロイキン－２ムテイン及びその使用 | |
| JP4624684B2 (ja) | ＣＤ２８と超抗原との相互作用に基づくｉｎ−ｖｉｖｏにて有効な広域スペクトルの超抗原毒素アンタゴニストおよびその使用 | |
| Fehlner et al. | Murine T cell responses to melittin and its analogs |